Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
作者信息
Patel Tejas K, Barvaliya Manish, Kevadiya Bhavesh D, Patel Parvati B, Bhalla Hira Lal
机构信息
Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur, Uttar Pradesh, 273008, India.
Department of Pharmacology, Government Medical College, Bhavnagar, Gujarat, 364001, India.
出版信息
J Neuroimmune Pharmacol. 2020 Sep;15(3):349. doi: 10.1007/s11481-020-09940-9. Epub 2020 Sep 2.
Abstract
摘要
相似文献
1
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.在标准治疗中添加羟氯喹对降低COVID-19患者死亡率是否有任何益处？一项系统评价。
J Neuroimmune Pharmacol. 2020 Sep;15(3):349. doi: 10.1007/s11481-020-09940-9. Epub 2020 Sep 2.
2
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.羟氯喹联合或不联合阿奇霉素对 COVID-19 患者死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26.
3
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials".羟氯喹在 COVID-19 中无益：随机对照试验的系统评价和荟萃分析结果。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1673-1680. doi: 10.1016/j.dsx.2020.08.033. Epub 2020 Sep 1.
4
Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review.羟氯喹啉与阿奇霉素联合使用对新冠肺炎患者的影响——一项综合评价
Indian J Community Med. 2024 Jan-Feb;49(1):22-27. doi: 10.4103/ijcm.ijcm_983_22. Epub 2024 Jan 12.
5
Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.羟氯喹治疗非住院 COVID-19 患者：随机临床试验的系统评价和荟萃分析。
Arq Bras Cardiol. 2023 Apr 7;120(4):e20220380. doi: 10.36660/abc.20220380. eCollection 2023.
6
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.阿奇霉素联合标准治疗与标准治疗单独用于治疗巴西因重度 COVID-19 住院患者（COALITION II）：一项随机临床试验。
Lancet. 2020 Oct 3;396(10256):959-967. doi: 10.1016/S0140-6736(20)31862-6. Epub 2020 Sep 5.
7
RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.撤稿：羟氯喹治疗 COVID-19 的多中心随机对照研究。
Am J Trop Med Hyg. 2020 Oct;103(4):1635-1639. doi: 10.4269/ajtmh.20-0873.
8
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
9
Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.羟氯喹治疗非重症 COVID-19 患者：对照临床试验的系统评价和荟萃分析。
J Med Virol. 2021 Mar;93(3):1265-1275. doi: 10.1002/jmv.26442. Epub 2020 Sep 29.
10
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients.羟氯喹缩短了住院 COVID-19 患者的住院时间，并减少了重症监护病房的入院人数。
J Infect Dev Ctries. 2022 Jan 31;16(1):25-31. doi: 10.3855/jidc.14933.
引用本文的文献
1
COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations.患有慢性心脏、呼吸和代谢疾病的成年患者中的 COVID-19：一项带有临床建议的批判性文献综述
Trop Dis Travel Med Vaccines. 2020 Aug 28;6:16. doi: 10.1186/s40794-020-00118-y. eCollection 2020.
2
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.羟氯喹联合或不联合阿奇霉素对 COVID-19 患者死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26.
本文引用的文献
1
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.羟氯喹联合标准治疗是否能降低 COVID-19 患者的死亡率？一项系统评价。
J Neuroimmune Pharmacol. 2020 Sep;15(3):350-358. doi: 10.1007/s11481-020-09930-x. Epub 2020 Sep 8.
2
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
Zotero 插件